FDA 483 - ZiphyCare, Inc. - September 06, 2022

An FDA inspection of ZiphyCare, Inc. in New York, NY, a specification developer, revealed significant deficiencies in their quality system. The firm failed to establish adequate procedures for supplier evaluation, design changes, document control, and software validation. These issues indicate a broad lack of control over their medical device development and manufacturing processes.